Talabostat

他波司他

Report date: 2024/04/19 11:57:29
NME

Base Information

Drug NameTalabostat
Drug Alias Name他柏司他TalabostatumValboroProVal-boroProTalabostat mesylate +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast activation protein alpha inhibitorsDipeptidyl peptidase IV inhibitorsDipeptidyl peptidase II inhibitors +[5] 
TargetsProlyl endopeptidase FAPDipeptidyl peptidase IVDipeptidyl peptidase II +[5] 
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[22] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPoint Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteGeorgetown UniversityBioxcel Therapeutics Inc
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Point TherapeuticsThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsMyelodysplastic SyndromesProstatic NeoplasmsCarcinoma, Small Cell +[6] 
Inactive IndicationsCNS Embryonal TumorSolid tumoursNeoplasm Metastasis +[16] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG